Skip to main content

Advertisement

Table 1 Adverse events, serious adverse events, deaths and discontinuations over the 26-weeks treatment period

From: COPD: maximization of bronchodilation

  Placebo QVA149110/50 μg Indacaterol 150 μg Glycopyrronium 50 μg Tiotropium 18 μg
Subjects, n 232 474 476 473 480
Patients with any adverse events 134 (57.8) 261 (55.1) 291 (61.1) 290 (61.3) 275 (57.3)
COPD 91 (39.2) 137 (28.9) 153 (32.1) 150 (31.7) 138 (28.8)
Nasopharyngitis 23 (9.9) 31 (6.5) 35 (7.4) 46 (9.7) 40 (8.3)
Cough 8 (3.4) 26 (5.5) 38 (8.0) 18 (3.8) 21 (4.4)
Upper respiratory tract infection 13 (5.6) 20 (4.2) 32 (6.7) 20 (4.2) 24 (5.0)
Oropharyngeal pain 7 (3.0) 17 (3.6) 7 (1.5) 10 (2.1) 10 (2.1)
Viral upper respiratory tract infection 7 (3.0) 15 (3.2) 11 (2.3) 13 (2.7) 12 (2.5)
Upper respiratory tract infection bacterial 13 (5.6) 10 (2.1) 13 (2.7) 15 (3.2) 22 (4.6)
Lower respiratory tract infection 5 (2.2) 9 (1.19) 15 (3.2) 7 (1.5) 12 (2.5)
Back pain 5 (2.2) 8 (1.17) 11 (2.3) 17 (3.6) 8 (1.7)
Serious adverse events 13 (5.6) 22 (4.6) 26 (5.5) 29 (6.1) 19 (4.0)
Adjudicated CCV events      
Atrial fibrillation/flutter (new onset) 0 2 (0.4) 3 (0.6) 2 (0.4) 1 (0.2)
Serious CCV events 1 (0.4) 0 6 (1.3) 7 (1.5) 4 (0.8)
MACE 0 0 2 (0.4) 3 (0.6) 3 (0.6)
  1. From [33].